抗菌薬耐性サーベイランス市場：コンポーネント別、エンドユーザー別-2025-2030年の世界予測

抗菌薬耐性サーベイランス市場は、2023年に56億米ドルと評価され、2024年には59億6,000万米ドルに達すると予想され、CAGR 6.49％で成長し、2030年には87億1,000万米ドルになると予測されています。

抗菌薬耐性（AMR）サーベイランスとは、病原体における抗菌薬耐性の流行とパターンに関連するデータの体系的な収集、分析、解釈を指します。この重要な公衆衛生ツールは、耐性がどのように広がっているかを監視し、抗菌薬の使用を指導し、新薬や治療プロトコルの開発に情報を提供するために必要です。AMRサーベイランスは、ヘルスケア施設、地域環境、国の保健システムを通じて適用され、病院、診断ラボ、研究機関、製薬会社、政府機関などをエンドユーザーとしています。この分野の市場成長は、薬剤耐性感染症の蔓延の増加、有効な選択肢の枯渇による新規抗菌薬の緊急の必要性、AMRに対する協調戦略を重視する世界の取り組みと並ぶ政府の支持的な政策によって影響を受けています。迅速診断検査のような技術の進歩や、官民両部門による研究開発への資金提供の増加は、大きな機会をもたらします。さらに、AIとビッグデータ分析が技術革新の可能性を提供し、調査手法を前進させています。しかし、この市場は、新しい診断技術に関連する高コストや、低リソース環境における限られた専門知識などの課題に直面しており、これが普及の障壁となっています。さらに、国によって異なる基準やサーベイランス能力によるデータの不一致が、世界の取り組みを複雑にしています。事業成長のためには、迅速診断の費用対効果とアクセシビリティの向上、予測モデリングのためのAIの活用、ポイント・オブ・ケア検査の拡大にイノベーションを集中させるべきです。国際的な保健機関との継続的な協力関係も戦略的優位性をもたらします。市場力学はダイナミックであり、ソリューションに対する緊急の需要を反映して、利害関係者は適応、国境を越えた協力、そして急速に進化する微生物の脅威に打ち勝つことができる革新的技術の統合を優先するよう求められています。

市場力学：急速に進化する抗菌薬耐性サーベイランス市場の主要市場インサイトを公開

抗菌薬耐性サーベイランス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 病原体による感染症の増加
  • 診断薬およびポイントオブケア診断の品質向上に対する政府のイニシアティブの高まり
• 市場抑制要因
  • 抗菌薬耐性サーベイランスに関連する高コスト
• 市場機会
  • 抗菌薬耐性（AMR）感染を管理するための高度な診断ソリューションに対する需要の高まり
  • 世界の診断薬認可の増加
• 市場の課題
  • AMRサーベイランスのための標準化された方法とガイドラインの欠如

ポーターのファイブフォース：抗菌薬耐性サーベイランス市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗菌薬耐性サーベイランス市場における外部からの影響の把握

外部マクロ環境要因は、抗菌薬耐性サーベイランス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗菌薬耐性サーベイランス市場における競合情勢の把握

抗菌薬耐性サーベイランス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗菌薬耐性サーベイランス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗菌薬耐性サーベイランス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗菌薬耐性サーベイランス市場における成功への道筋を描く

抗菌薬耐性サーベイランス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 病原体による感染症の蔓延の増加
    • 診断とポイントオブケア診断の質を向上させるための政府の取り組みが増加
  • 抑制要因
    • 抗菌薬耐性サーベイランスに関連する高コスト
  • 機会
    • 抗菌薬耐性（AMR）感染症を管理するための高度な診断ソリューションに対する需要の高まり
    • 世界中で診断製品の規制承認が増加
  • 課題
    • AMR監視のための標準化された方法とガイドラインの欠如
• 市場セグメンテーション分析
  • 構成要素：比較的低コストで特定の耐性マーカーを迅速に検出する診断キットの重要な役割
  • エンドユーザー：院内感染の発生率の増加により、次世代の抗菌薬耐性（AMR）監視の必要性が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 抗菌薬耐性サーベイランス市場：コンポーネント別

• 診断キット
• 診断システム
• サービス
• ソフトウェア

第7章 抗菌薬耐性サーベイランス市場：エンドユーザー別

• 病院
• 調査・学術機関

第8章 南北アメリカの抗菌薬耐性サーベイランス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の抗菌薬耐性サーベイランス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの抗菌薬耐性サーベイランス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • AI駆動型AMRxツールによる高度な抗菌薬耐性診断と治療、精度と患者の転帰の向上
  • ヴィスビー・メディカル、抗生物質耐性スクリーニング機能を備えたポータブル淋病検査の進歩に向けて180万米ドルを確保
  • ノボ・ホールディングス、パラテック・ファーマシューティカルズを買収し薬剤耐性感染症との戦いを強化
  • AMRアクション基金、抗生物質耐性対策への投資を拡大
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Accelerate Diagnostics, Inc.
• acquired by bioMerieux SA
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• Bruker Corporation
• Cepheid by Danaher Corporation
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Hologic, Inc.
• Illumina, Inc.
• Johnson & Johnson Services Inc.
• Liofilchem S.r.l.
• Luminex Corporation by DiaSorin S.p.A.
• Merck & Co., Inc.
• Novo Holdings A/S
• OpGen, Inc.
• Pfizer Inc.
• QIAGEN GmbH
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Venatorx Pharmaceuticals, Inc.
• Viatris Inc.
• Vivli Inc.
• Wolters Kluwer N.V.

LIST OF FIGURES

• FIGURE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET RESEARCH PROCESS
• FIGURE 2. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. CANADA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 23. CANADA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 35. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 37. INDIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ITALY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 72. ITALY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. POLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 80. POLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. QATAR ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 82. QATAR ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2023

The Antimicrobial Resistance Surveillance Market was valued at USD 5.60 billion in 2023, expected to reach USD 5.96 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 8.71 billion by 2030.

Antimicrobial resistance (AMR) surveillance refers to the systematic collection, analysis, and interpretation of data related to the prevalence and patterns of antimicrobial resistance in pathogens. This critical public health tool is necessary to monitor how resistance is spreading, to guide the use of antimicrobial agents, and to inform on the development of new drugs and treatment protocols. AMR surveillance is applied within healthcare facilities, community settings, and through national health systems, with an end-user scope that includes hospitals, diagnostic labs, research institutes, pharmaceutical companies, and governmental bodies. Market growth in this field is influenced by the increasing prevalence of drug-resistant infections, the urgent need for novel antimicrobials due to the depletion of effective options, and supportive government policies alongside global initiatives that emphasize collaborative strategies against AMR. Technological advancements, like rapid diagnostic tests, and increased funding for R&D by both public and private sectors present significant opportunities. Additionally, AI and big data analytics are offering potential avenues for innovation, driving forward surveillance methodologies. However, the market faces challenges, including high costs associated with novel diagnostic technologies and limited expertise in low-resource settings, which represents a barrier to widespread implementation. Furthermore, discrepancies in data due to varying standards and surveillance capacities across nations complicate global efforts. For business growth, innovation should focus on enhancing cost-effectiveness and accessibility of rapid diagnostics, exploiting AI for predictive modeling, and expanding point-of-care testing. Continuous collaboration with international health organizations can also provide strategic advantages. The market's nature is dynamic, reflecting an urgent demand for solutions, pushing stakeholders to prioritize adaptation, cross-border collaboration, and the integration of innovative technologies that can outpace rapidly evolving microbial threats.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Resistance Surveillance Market

The Antimicrobial Resistance Surveillance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of infections caused by pathogens
  • Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
• Market Restraints
  • High cost associated with antimicrobial resistance surveillance
• Market Opportunities
  • Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
  • Increasing regulatory approvals of diagnostics products worldwide
• Market Challenges
  • Lack of standardized methods and guidelines for AMR surveillance

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Resistance Surveillance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Resistance Surveillance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Resistance Surveillance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Resistance Surveillance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Resistance Surveillance Market

A detailed market share analysis in the Antimicrobial Resistance Surveillance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Resistance Surveillance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Resistance Surveillance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimicrobial Resistance Surveillance Market

A strategic analysis of the Antimicrobial Resistance Surveillance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Resistance Surveillance Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., acquired by bioMerieux SA, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Hologic, Inc., Illumina, Inc., Johnson & Johnson Services Inc., Liofilchem S.r.l., Luminex Corporation by DiaSorin S.p.A., Merck & Co., Inc., Novo Holdings A/S, OpGen, Inc., Pfizer Inc., QIAGEN GmbH, Sanofi S.A., Thermo Fisher Scientific Inc., Venatorx Pharmaceuticals, Inc., Viatris Inc., Vivli Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Resistance Surveillance Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Diagnostic Kits, Diagnostic Systems, Services, and Software.
• Based on End-User, market is studied across Hospitals and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infections caused by pathogens
    • 5.1.1.2. Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with antimicrobial resistance surveillance
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
    • 5.1.3.2. Increasing regulatory approvals of diagnostics products worldwide
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standardized methods and guidelines for AMR surveillance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Component: Significant role of diagnostic kits in offering rapid detection of specific resistance markers at relatively lower costs
  • 5.2.2. End-User: Increasing incidence of hospital-acquired infections developed necessities for next generation antimicrobial resistance (AMR) surveillance
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antimicrobial Resistance Surveillance Market, by Component

• 6.1. Introduction
• 6.2. Diagnostic Kits
• 6.3. Diagnostic Systems
• 6.4. Services
• 6.5. Software

7. Antimicrobial Resistance Surveillance Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Research & Academic Institutes

8. Americas Antimicrobial Resistance Surveillance Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Antimicrobial Resistance Surveillance Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Antimicrobial Resistance Surveillance Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. AI-Driven AMRx Tool Advanced Antimicrobial Resistance Diagnosis and Treatment, Enhancing Accuracy and Patient Outcomes
  • 11.3.2. Visby Medical Secures USD 1.8 Million to Advance Portable Gonorrhea Test with Antibiotic Resistance Screening
  • 11.3.3. Novo Holdings Strengthens Fight Against Drug-Resistant Infections by Acquiring Paratek Pharmaceuticals
  • 11.3.4. AMR Action Fund Expands Investment Efforts to Tackle Antibiotic Resistance
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Accelerate Diagnostics, Inc.
• 3. acquired by bioMerieux SA
• 4. Agilent Technologies, Inc.
• 5. Becton, Dickinson and Company
• 6. bioMerieux SA
• 7. Bruker Corporation
• 8. Cepheid by Danaher Corporation
• 9. F. Hoffmann-La Roche Ltd
• 10. GlaxoSmithKline PLC
• 11. Hologic, Inc.
• 12. Illumina, Inc.
• 13. Johnson & Johnson Services Inc.
• 14. Liofilchem S.r.l.
• 15. Luminex Corporation by DiaSorin S.p.A.
• 16. Merck & Co., Inc.
• 17. Novo Holdings A/S
• 18. OpGen, Inc.
• 19. Pfizer Inc.
• 20. QIAGEN GmbH
• 21. Sanofi S.A.
• 22. Thermo Fisher Scientific Inc.
• 23. Venatorx Pharmaceuticals, Inc.
• 24. Viatris Inc.
• 25. Vivli Inc.
• 26. Wolters Kluwer N.V.